Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252642 · ClinicalTrials.gov registry record · NA
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00252642 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 60 participants.
The verdict
NCT00252642, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
Interventions
- DRUG Peginterferon Alpha-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252642
The ClinicalTrials.gov registry entry for NCT00252642 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peginterferon Alpha-2a is the first listed.
NCT00252642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252642 about?
NCT00252642 is a clinical study titled "Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C". The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
What is the current status of trial NCT00252642?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2005-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00252642?
The interventions under investigation include: Peginterferon Alpha-2a (DRUG).
Who is sponsoring clinical trial NCT00252642?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.